The vascular disrupting agent combretastatin A-4 phosphate causes prolonged elevation of proteins involved in heme flux and function in resistant tumor cells

Sanchareeka Dey, Sharda Kumari, Sarada Preeta Kalainayakan, James Campbell, Poorva Ghosh, Heling Zhou, Keely E. FitzGerald, Maoping Li, Ralph P. Mason, Li Zhang, Li Liu

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Vascular disrupting agents (VDAs) represent a promising class of anti-cancer drugs for solid tumor treatment. Here, we aim to better understand the mechanisms underlying tumor reccurrence and treatment resistance following the administration of a VDA, combretastatin A-4 phosphate (CA4P). Firstly, we used photoacoustic tomography to noninvasively map the effect of CA4P on blood oxygen levels throughout subcutaneous non-small cell lung cancer (NSCLC) tumors in mice. We found that the oxygenation of peripheral tumor vessels was significantly decreased at 1 and 3 hours post-CA4P treatment. The oxygenation of the tumor core reduced significantly at 1 and 3 hours, and reached anoxia after 24 hours. Secondly, we examined the effect of CA4P on the levels of proteins involved in heme flux and function, which are elevated in lung tumors. Using immunohistochemistry, we found that CA4P substantially enhanced the levels of enzymes involved in heme biosynthesis, uptake, and degradation, as well as oxygen-utilizing hemoproteins. Furthermore, measurements of markers of mitochondrial function suggest that CA4P did not diminish mitochondrial function in resistant tumor cells. These results suggest that elevated levels of heme flux and function contribute to tumor regrowth and treatment resistance post-VDA administration.

Original languageEnglish (US)
Pages (from-to)4090-4101
Number of pages12
JournalOncotarget
Volume9
Issue number3
DOIs
StatePublished - Jan 1 2018

Fingerprint

Heme
Blood Vessels
Phosphates
Neoplasms
Proteins
Oxygen
fosbretabulin
Therapeutics
Non-Small Cell Lung Carcinoma
Vascular Resistance
Immunohistochemistry
Tomography
Lung
Enzymes
Pharmaceutical Preparations

Keywords

  • Combretastatin A-4 phosphate (CA4P)
  • Heme
  • Lung tumor
  • Multispectral optoacoustic tomography (MSOT)
  • Vascular disrupting agent (VDA)

ASJC Scopus subject areas

  • Oncology

Cite this

The vascular disrupting agent combretastatin A-4 phosphate causes prolonged elevation of proteins involved in heme flux and function in resistant tumor cells. / Dey, Sanchareeka; Kumari, Sharda; Kalainayakan, Sarada Preeta; Campbell, James; Ghosh, Poorva; Zhou, Heling; FitzGerald, Keely E.; Li, Maoping; Mason, Ralph P.; Zhang, Li; Liu, Li.

In: Oncotarget, Vol. 9, No. 3, 01.01.2018, p. 4090-4101.

Research output: Contribution to journalArticle

Dey, Sanchareeka ; Kumari, Sharda ; Kalainayakan, Sarada Preeta ; Campbell, James ; Ghosh, Poorva ; Zhou, Heling ; FitzGerald, Keely E. ; Li, Maoping ; Mason, Ralph P. ; Zhang, Li ; Liu, Li. / The vascular disrupting agent combretastatin A-4 phosphate causes prolonged elevation of proteins involved in heme flux and function in resistant tumor cells. In: Oncotarget. 2018 ; Vol. 9, No. 3. pp. 4090-4101.
@article{e74cff78448e4cc6bf304cda857e5cdb,
title = "The vascular disrupting agent combretastatin A-4 phosphate causes prolonged elevation of proteins involved in heme flux and function in resistant tumor cells",
abstract = "Vascular disrupting agents (VDAs) represent a promising class of anti-cancer drugs for solid tumor treatment. Here, we aim to better understand the mechanisms underlying tumor reccurrence and treatment resistance following the administration of a VDA, combretastatin A-4 phosphate (CA4P). Firstly, we used photoacoustic tomography to noninvasively map the effect of CA4P on blood oxygen levels throughout subcutaneous non-small cell lung cancer (NSCLC) tumors in mice. We found that the oxygenation of peripheral tumor vessels was significantly decreased at 1 and 3 hours post-CA4P treatment. The oxygenation of the tumor core reduced significantly at 1 and 3 hours, and reached anoxia after 24 hours. Secondly, we examined the effect of CA4P on the levels of proteins involved in heme flux and function, which are elevated in lung tumors. Using immunohistochemistry, we found that CA4P substantially enhanced the levels of enzymes involved in heme biosynthesis, uptake, and degradation, as well as oxygen-utilizing hemoproteins. Furthermore, measurements of markers of mitochondrial function suggest that CA4P did not diminish mitochondrial function in resistant tumor cells. These results suggest that elevated levels of heme flux and function contribute to tumor regrowth and treatment resistance post-VDA administration.",
keywords = "Combretastatin A-4 phosphate (CA4P), Heme, Lung tumor, Multispectral optoacoustic tomography (MSOT), Vascular disrupting agent (VDA)",
author = "Sanchareeka Dey and Sharda Kumari and Kalainayakan, {Sarada Preeta} and James Campbell and Poorva Ghosh and Heling Zhou and FitzGerald, {Keely E.} and Maoping Li and Mason, {Ralph P.} and Li Zhang and Li Liu",
year = "2018",
month = "1",
day = "1",
doi = "10.18632/oncotarget.23734",
language = "English (US)",
volume = "9",
pages = "4090--4101",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals",
number = "3",

}

TY - JOUR

T1 - The vascular disrupting agent combretastatin A-4 phosphate causes prolonged elevation of proteins involved in heme flux and function in resistant tumor cells

AU - Dey, Sanchareeka

AU - Kumari, Sharda

AU - Kalainayakan, Sarada Preeta

AU - Campbell, James

AU - Ghosh, Poorva

AU - Zhou, Heling

AU - FitzGerald, Keely E.

AU - Li, Maoping

AU - Mason, Ralph P.

AU - Zhang, Li

AU - Liu, Li

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Vascular disrupting agents (VDAs) represent a promising class of anti-cancer drugs for solid tumor treatment. Here, we aim to better understand the mechanisms underlying tumor reccurrence and treatment resistance following the administration of a VDA, combretastatin A-4 phosphate (CA4P). Firstly, we used photoacoustic tomography to noninvasively map the effect of CA4P on blood oxygen levels throughout subcutaneous non-small cell lung cancer (NSCLC) tumors in mice. We found that the oxygenation of peripheral tumor vessels was significantly decreased at 1 and 3 hours post-CA4P treatment. The oxygenation of the tumor core reduced significantly at 1 and 3 hours, and reached anoxia after 24 hours. Secondly, we examined the effect of CA4P on the levels of proteins involved in heme flux and function, which are elevated in lung tumors. Using immunohistochemistry, we found that CA4P substantially enhanced the levels of enzymes involved in heme biosynthesis, uptake, and degradation, as well as oxygen-utilizing hemoproteins. Furthermore, measurements of markers of mitochondrial function suggest that CA4P did not diminish mitochondrial function in resistant tumor cells. These results suggest that elevated levels of heme flux and function contribute to tumor regrowth and treatment resistance post-VDA administration.

AB - Vascular disrupting agents (VDAs) represent a promising class of anti-cancer drugs for solid tumor treatment. Here, we aim to better understand the mechanisms underlying tumor reccurrence and treatment resistance following the administration of a VDA, combretastatin A-4 phosphate (CA4P). Firstly, we used photoacoustic tomography to noninvasively map the effect of CA4P on blood oxygen levels throughout subcutaneous non-small cell lung cancer (NSCLC) tumors in mice. We found that the oxygenation of peripheral tumor vessels was significantly decreased at 1 and 3 hours post-CA4P treatment. The oxygenation of the tumor core reduced significantly at 1 and 3 hours, and reached anoxia after 24 hours. Secondly, we examined the effect of CA4P on the levels of proteins involved in heme flux and function, which are elevated in lung tumors. Using immunohistochemistry, we found that CA4P substantially enhanced the levels of enzymes involved in heme biosynthesis, uptake, and degradation, as well as oxygen-utilizing hemoproteins. Furthermore, measurements of markers of mitochondrial function suggest that CA4P did not diminish mitochondrial function in resistant tumor cells. These results suggest that elevated levels of heme flux and function contribute to tumor regrowth and treatment resistance post-VDA administration.

KW - Combretastatin A-4 phosphate (CA4P)

KW - Heme

KW - Lung tumor

KW - Multispectral optoacoustic tomography (MSOT)

KW - Vascular disrupting agent (VDA)

UR - http://www.scopus.com/inward/record.url?scp=85040175439&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85040175439&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.23734

DO - 10.18632/oncotarget.23734

M3 - Article

VL - 9

SP - 4090

EP - 4101

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 3

ER -